Search research articles
Contact Us
Filters
Showing results (141-150 of 185) with videos related to
Page
of 19
Sort By:
Scientific Reports
|
May 3, 2022
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2025
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial
Cihan Gani, Emmanouil Fokas, Bülent Polat, et al.
Gastro Hep Advances
|
February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects
Louise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Future Oncology (London, England)
|
January 27, 2022
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
Najib Ben Khaled, Max Seidensticker, Jens Ricke, et al.
Nature Communications
|
February 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches
Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Claudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Nature Communications
|
April 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Neuro-Oncology Advances
|
March 24, 2026
Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort
David Rieger, Hannes Becker, Bianca Walter, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 185) with videos related to
Sort By:
Page
of 19
Scientific Reports
|
May 3, 2022
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2025
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial
Cihan Gani, Emmanouil Fokas, Bülent Polat, et al.
Gastro Hep Advances
|
February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects
Louise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Future Oncology (London, England)
|
January 27, 2022
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
Najib Ben Khaled, Max Seidensticker, Jens Ricke, et al.
Nature Communications
|
February 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches
Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Claudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Nature Communications
|
April 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Neuro-Oncology Advances
|
March 24, 2026
Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort
David Rieger, Hannes Becker, Bianca Walter, et al.
Page
of 19